Literature DB >> 26911398

Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview.

J E G IJspeert1, R Bevan2, C Senore3, M F Kaminski4,5, E J Kuipers6, A Mroz7, X Bessa8, P Cassoni9, C Hassan10, A Repici11, F Balaguer12, C J Rees2, E Dekker1.   

Abstract

OBJECTIVE: The role of serrated polyps (SPs) as colorectal cancer precursor is increasingly recognised. However, the true prevalence SPs is largely unknown. We aimed to evaluate the detection rate of SPs subtypes as well as serrated polyposis syndrome (SPS) among European screening cohorts.
METHODS: Prospectively collected screening cohorts of ≥1000 individuals were eligible for inclusion. Colonoscopies performed before 2009 and/or in individuals aged below 50 were excluded. Rate of SPs was assessed, categorised for histology, location and size. Age-sex-standardised number needed to screen (NNS) to detect SPs were calculated. Rate of SPS was assessed in cohorts with known colonoscopy follow-up data. Clinically relevant SPs (regarded as a separate entity) were defined as SPs ≥10 mm and/or SPs >5 mm in the proximal colon.
RESULTS: Three faecal occult blood test (FOBT) screening cohorts and two primary colonoscopy screening cohorts (range 1.426-205.949 individuals) were included. Rate of SPs ranged between 15.1% and 27.2% (median 19.5%), of sessile serrated polyps between 2.2% and 4.8% (median 3.3%) and of clinically relevant SPs between 2.1% and 7.8% (median 4.6%). Rate of SPs was similar in FOBT-based cohorts as in colonoscopy screening cohorts. No apparent association between the rate of SP and gender or age was shown. Rate of SPS ranged from 0% to 0.5%, which increased to 0.4% to 0.8% after follow-up colonoscopy.
CONCLUSIONS: The detection rate of SPs is variable among screening cohorts, and standards for reporting, detection and histopathological assessment should be established. The median rate, as found in this study, may contribute to define uniform minimum standards for males and females between 50 and 75 years of age. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COLONOSCOPY; COLORECTAL CANCER; COLORECTAL NEOPLASIA; POLYPOSIS

Mesh:

Year:  2016        PMID: 26911398     DOI: 10.1136/gutjnl-2015-310784

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Clinical study of anesthetization by dezocine combined with propofol for indolent colonoscopy.

Authors:  Bin-Bin Xu; Xiao-Liang Zhao; Gui-Ping Xu
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  Providing data for serrated polyp detection rate benchmarks: an analysis of the New Hampshire Colonoscopy Registry.

Authors:  Joseph C Anderson; Lynn F Butterly; Julia E Weiss; Christina M Robinson
Journal:  Gastrointest Endosc       Date:  2017-01-31       Impact factor: 9.427

3.  Serrated polyposis: the problem of definition and its relationship to the population at risk for syndrome-related colorectal cancer.

Authors:  Joanne P Young; Timothy J Price; Susan Parry
Journal:  Transl Cancer Res       Date:  2017-12       Impact factor: 1.241

Review 4.  The Natural History of Colorectal Polyps: Overview of Predictive Static and Dynamic Features.

Authors:  Perry J Pickhardt; Bryan Dustin Pooler; David H Kim; Cesare Hassan; Kristina A Matkowskyj; Richard B Halberg
Journal:  Gastroenterol Clin North Am       Date:  2018-06-29       Impact factor: 3.806

5.  The (ir)relevance of the abandoned criterion II for the diagnosis of serrated polyposis syndrome: a retrospective cohort study.

Authors:  Arne G C Bleijenberg; Joep E G IJspeert; Daniel Rodríguez-Alcalde; Sabela Carballal; Maurits R Visser; Maria Pellise; Jan Jacob Koornstra; Salman A Rana; Andrew Latchford; Francesc Balaguer; Evelien Dekker
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

6.  Modifiable lifestyle factors associated with risk of sessile serrated polyps, conventional adenomas and hyperplastic polyps.

Authors:  James R Davenport; Timothy Su; Zhiguo Zhao; Helen G Coleman; Walter E Smalley; Reid M Ness; Wei Zheng; Martha J Shrubsole
Journal:  Gut       Date:  2016-11-15       Impact factor: 23.059

Review 7.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.

Authors:  Priyanka Kanth; Jade Grimmett; Marjan Champine; Randall Burt; N Jewel Samadder
Journal:  Am J Gastroenterol       Date:  2017-08-08       Impact factor: 10.864

8.  Low Sensitivity of Fecal Immunochemical Tests and Blood-Based Markers of DNA Hypermethylation for Detection of Sessile Serrated Adenomas/Polyps.

Authors:  Charles Cock; Shahzaib Anwar; Susan E Byrne; Rosie Meng; Susanne Pedersen; Robert J L Fraser; Graeme P Young; Erin L Symonds
Journal:  Dig Dis Sci       Date:  2019-03-05       Impact factor: 3.199

Review 9.  Hereditary or Not? Understanding Serrated Polyposis Syndrome.

Authors:  Peter P Stanich; Rachel Pearlman
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 10.  Advanced Endoscopic Imaging in Colonic Neoplasia.

Authors:  Timo Rath; Nadine Morgenstern; Francesco Vitali; Raja Atreya; Markus F Neurath
Journal:  Visc Med       Date:  2020-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.